Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (39,064)	$ (27,564)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	9,042	10,198
Depreciation and amortization	1,557	422
Non-cash interest	102	135
Deferred income tax benefit	(2,106)	(748)
Changes in operating assets and liabilities:
Accounts receivable	2,519	991
Research and development incentives receivable	(6,830)	(2,774)
Prepaid expenses and other assets	(1,735)	(1,341)
Operating lease right-of-use assets	1,009	650
Accounts payable	(2,001)	(255)
Accrued expenses and other current liabilities	(3,130)	(2,337)
Operating lease liabilities	(1,034)	(105)
Deferred revenue	(4,900)	(3,850)
Other long-term liabilities	160	178
Net cash used in operating activities	(46,411)	(26,400)
Cash used in investing activities:
Purchases of property and equipment	(2,099)	(4,756)
Net cash used in investing activities	(2,099)	(4,756)
Cash flows from financing activities:
Proceeds from the issuance of ADSs, net of issuance costs	2,716
Proceeds from the exercise of share options and sale of ordinary shares	2	450
Net cash provided by financing activities	2,718	450
Effect of exchange rate changes on cash and cash equivalents	453	(603)
Net decrease in cash and cash equivalents	(45,339)	(31,309)
Cash and cash equivalents at beginning of period	339,154	438,680
Cash and cash equivalents at end of period	293,815	407,371
Supplemental disclosure of cash flow information
Cash paid for interest	679	664
Cash paid for income taxes		(35)
Cash paid for amounts included in the measurement of operating lease liabilities	1,351	375
Changes in purchases of property and equipment in accounts payable and accrued expenses	(1,737)	1,630
Advance billings on deferred revenue included in accounts receivable	50,000
Non-cash impact right-of-use asset and operating lease liabilities	$ 5,849	$ 3,120